Regarding "impact of cilostazol after endovascular treatment for infrainguinal disease in patients with critical limb ischemia"

Journal of Vascular Surgery

Volumn 55, Issue 3, 2012, Pages 891-

  Dindyal, Shiva ^a   Kyriakides, Constantinos ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CILOSTAZOL;

CLAUDICATION; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; CRITICAL LIMB ISCHEMIA; HEALTH CARE ORGANIZATION; INFRAINGUINAL DISEASE; LETTER; LIMB ISCHEMIA; MEDICAL INFORMATION; NATIONAL HEALTH SERVICE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; TREATMENT INDICATION;

ANGIOPLASTY, BALLOON; ARTERIAL OCCLUSIVE DISEASES; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; ISCHEMIA; LOWER EXTREMITY; MALE; TETRAZOLES;

EID: 84857519669     PISSN: 07415214     EISSN: 10976809     Source Type: Journal    
DOI: 10.1016/j.jvs.2011.10.133     Document Type: Letter

References (3)

1. Y. Soga, O. Iida, K. Hirano, K. Suzuki, D. Kawasaki, Y. Miyashita Impact of cilostazol after endovascular treatment for infrainguinal disease in patients with critical limb ischemia J Vasc Surg 54 2011 1659 1667
2. S. Dindyal, C. Kyriakides A review of cilostazol, a phosphodiesterase inhibitor, and its role in preventing both coronary and peripheral arterial restenosis following endovascular therapy Recent Pat Cardiovasc Drug Discov 4 2009 6 14
3. National Institute for Health and Clinical Excellence Cilostazol, naftidrofyryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease Technology appraisals TA223: May 2011 http://guidance.nice.org.uk/TA223 Accessed October 9, 2011